Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Nelwan E.J.; Herdiman A.; Kalaij A.G.I.; Lauditta R.K.; Yusuf S.M.; Suarthana E.
Nelwan, Erni Juwita (14527452900); Herdiman, Allerma (59139501200); Kalaij, Ayers Gilberth Ivano (57223906853); Lauditta, Richella Khansa (57790589800); Yusuf, Syarif Maulana (57359274400); Suarthana, Eva (8917676900)
14527452900; 59139501200; 57223906853; 57790589800; 57359274400; 8917676900
Role of probiotic as adjuvant in treating various infections: a systematic review and meta-analysis
2024
BMC Infectious Diseases
24
1
505
0
Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Infectious Disease and Immunology Research Center, Indonesia Medical and Education Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Health Technology Assessment Unit (TAU) of the McGill University Health Center, Montreal, Canada
Nelwan E.J., Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia, Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia, Infectious Disease and Immunology Research Center, Indonesia Medical and Education Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Herdiman A., Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Kalaij A.G.I., Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Lauditta R.K., Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Yusuf S.M., Infectious Disease and Immunology Research Center, Indonesia Medical and Education Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Suarthana E., Health Technology Assessment Unit (TAU) of the McGill University Health Center, Montreal, Canada
Background: Research on the advantages of probiotics has attracted increasing interest based on the number of publications, products, and public awareness of their benefits. This review evaluated the role of probiotics (single and multiple regimens) as an additional regimen to treat common infectious diseases, including Helicobacter. pylori, diarrheal infections, urinary tract infections (UTIs), upper respiratory tract infections (URTIs), and HIV infections. Methods: We searched randomized controlled trials from PubMed, Scopus, Embase, and Cochrane and identified 6,950 studies. Duplicates were removed, and titles and abstracts were filtered. Bias was evaluated using the Cochrane Risk of Bias Tool for Randomized Trials (ROB 1.0 and 2.0). The certainty of the evidence was evaluated using GRADE. Data were extracted and meta-analysis was performed using RevMan. Results: A total of 32 studies were included in this study (22 H. pylori studies, 2 diarrheal infection studies, 6 UTI studies, and 2 HIV infection studies). There was no study on URTI. Probiotics, in addition to primary treatment, could improve the eradication of H. pylori versus the control (RR: 1.09; 95% CI:1.04 − 1.13, p value = 0.001) and achieve a cure range of Nugent score in UTI patients (RR 1.38; 95% CI: 1.01 − 1.89, p value = 0.04). For eradicating H. pylori infection, subgroup analysis based on the therapy regimen showed that standard triple therapy was slightly superior compared to quadruple therapy in eradicating H. pylori (RR: 1.14 vs. 1.01, respectively). Single strain probiotics showed a similar effect to multiple strain probiotic regimens (both had an RR of 1.09). The effect estimates of the use of single strain probiotics as adjuvant therapy in eradicating H. pylori and the use of probiotics in UTI had a high certainty of evidence. Meta-analysis was not performed for infectious diarrheal because there were only two eligible studies with different probiotic supplementations and outcome parameters. Nonetheless, they showed that the diarrheal incidence was lower and complete remission of diarrheal was higher after the regimen of probiotics. Similarly, a meta-analysis was not performed for HIV infection because the two eligible studies used different designs and comparators with contradicting findings. Conclusion: This meta-analysis showed beneficial use of single strain probiotics as adjuvant therapy in eradicating H. pylori and the use of probiotics in UTI. Probiotic supplementation might not be beneficial for patients given a quadruple therapy. Single-strain and multi-strain probiotic regimens had similar effects in increasing the eradication rate of H. pylori. Our study also suggested that the benefits of probiotics as an additional regimen in infectious diarrheal and HIV infections remain unclear; more studies are needed to confirm the benefits. © The Author(s) 2024.
Diarrheal infection; Helicobacter pylori; Human immunodeficiency virus; Probiotics; Urinary tract infection
Diarrhea; Helicobacter Infections; Helicobacter pylori; HIV Infections; Humans; Probiotics; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Treatment Outcome; Urinary Tract Infections; probiotic agent; probiotic agent; antiretroviral therapy; bacterial clearance; Bifidobacterium; CD4 lymphocyte count; diarrhea; follow up; GRADE approach; Helicobacter infection; human; Human immunodeficiency virus infection; meta analysis; quadruple chemotherapy; quality control; randomized controlled trial (topic); respiratory tract infection; Review; sensitivity analysis; systematic review; urinary tract infection; diarrhea; drug effect; drug therapy; Helicobacter infection; Helicobacter pylori; Human immunodeficiency virus infection; microbiology; prevention and control; respiratory
BioMed Central Ltd
14712334
38773400
Review
Q1
1031
4223